Compare Plby Group Inc (PLBY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Smith & Nephew plc — how do they compare? Plby Group Inc trades at $1.16 (market cap $141.97M), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Smith & Nephew plc is far larger — about 81.9× Plby Group Inc's market cap, and Smith & Nephew plc pays a 2.85% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| PLBY | SNN | |
|---|---|---|
Market Cap | $141.97M | $11.63B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $38.53 |
52-Week Low | $1.11 | $27.80 |
Enterprise Value | $287.56M | $14.66B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $1.18, showing modest daily gains but remains in a technical downtrend. The company demonstrates improving fundamentals with revenue stabilizing around $120M and narrowing losses, though profitability remains elusive. Recent positive developments include Q2 2026 earnings beat, inclusion in Russell indexes, and strategic share repurchases. Analyst sentiment leans bullish with 75% buy ratings, yet technical indicators signal caution with bearish moving averages.
The outlook suggests cautious optimism as PLBY transitions toward profitability, supported by licensing growth and cost management. Key opportunities include brand monetization and market share gains, while risks involve high debt levels, negative equity, and competitive pressures. Investors should monitor execution on profitability targets and debt reduction progress for sustained recovery.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
